Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$3.50 – $3.65
Volume3,819
Market cap$54M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for INCR.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for INCR.
Recent news
Company coverage with links to the original publishers.
InterCure Ltd. announced a binding term sheet for NIS 22 million (approximately US$7.4 million) in private placement financing, with potential to increase to NIS 54 million. The funding includes investments from CEO Alexander Rabinovich and leading pharma-focused hedge funds including Bennu Pharma Fund Ltd. The company plans to use proceeds for global expansion, particularly in Germany and U.S. regulated medical cannabis markets, as well as recovery and expansion of its Nir Oz facility.
InterCure Ltd. (Nasdaq: INCR) received a notice from Nasdaq on February 25, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-calendar day compliance period until August 24, 2026, to regain compliance. InterCure plans to consider a reverse share split as part of its strategy to meet the requirement. The company's shares will continue trading on Nasdaq during this period.
InterCure reported preliminary 2025 revenue of NIS 265 million, representing 11% growth year-over-year with nearly 20% growth in H2 2025. The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA and generated first significant revenues from the German market. The company also announced strategic acquisitions of Botanico Ltd. and a 28% stake in Cannasoul R&D Ltd., along with NIS 81 million in war-related compensation advances from Israeli authorities.
InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI), gaining access to advanced AI-driven cultivation technologies and exclusive US cannabis brand partnerships, positioning itself for potential industry expansion amid potential cannabis rescheduling.
InterCure reported revenue of NIS 126 million and adjusted EBITDA of NIS 21 million for the first half of 2024. The company's southern facility was affected by a terrorist attack and the war in Gaza, but it is entitled to compensation from the Israeli authorities. InterCure plans to expand its partnership with Cookies and launch products in Germany and the UK.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.